A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy-Reference-Cited by-同舟云学术

A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy

Published:2023-10-29 Issue: Volume: Page:
ISSN:0971-4502
Container-title:Indian Journal of Hematology and Blood Transfusion
language:en
Short-container-title:Indian J Hematol Blood Transfus

Author:

Boppana Mounika,Sengar Manju^ORCID,Jain Hasmukh^ORCID,Gurjar Murari,Ambotkar Madhavi,Gota Vikram^ORCID,Bonda Avinash,Bagal Bhausaheb^ORCID,Thorat Jayashree,Gokarn Anant,Nayak Lingaraj^ORCID,Shetty Nitin,Baheti Akshay,Mokal Smruti,Kannan Sadhana,Shetty Alok,Eipe Thomas^ORCID

Funder

Tata Memorial Centre Research Administrative Council

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12288-023-01709-3.pdf

Reference50 articles.

1. Barchiesi F, Schimizzi AM, Caselli F et al (2001) Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48(6):769–773. https://doi.org/10.1093/jac/48.6.769

2. Cacciapuoti A, Loebenberg D, Corcoran E et al (2000) In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 44(8):2017–2022. https://doi.org/10.1128/AAC.44.8.2017-2022.2000

3. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46(2):229–234. https://doi.org/10.1093/jac/46.2.229

4. Pfaller MA, Messer SA, Hollis RJ, Jones RN (2001) In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 45(10):2862–2864. https://doi.org/10.1128/AAC.45.10.2862-2864.2001

5. Pfaller MA, Messer SA, Hollis RJ, Jones RN (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46(4):1032–1037. https://doi.org/10.1128/AAC.46.4.1032-1037.2002

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches for posaconazole therapeutic drug monitoring and their clinical benefits;European Journal of Clinical Pharmacology;2024-09-09